Collaboration expands genomic testing in clinical trials

Biofidelity, a leader in innovative genomic solutions, has entered into a strategic partnership with CellCarta, a global contract research organisation (CRO) specialising in precision medicine solutions. This collaboration will integrate Biofidelity’s Aspyre® Lung assay into CellCarta’s clinical trial services, expanding access to advanced genomic testing worldwide.

Aspyre Lung streamlines the detection of key non-small cell lung cancer (NSCLC) biomarkers by analysing both DNA and RNA from tissue and blood samples. Utilising a simple four-step workflow, it operates on existing qPCR platforms, making it a seamless addition to clinical laboratories. By incorporating this technology, CellCarta aims to enhance its biomarker testing capabilities, supporting efficient and reliable patient enrollment in clinical trials.

Under the agreement, CellCarta will first establish and validate Aspyre Lung in its European laboratories before expanding to its US-based facilities. The partnership grants CellCarta non-exclusive rights to utilise Aspyre Lung for clinical trials globally, offering pharmaceutical and biotech companies access to cutting-edge genomic profiling for both liquid and tissue biopsy samples.

“We are thrilled to collaborate with CellCarta to bring Aspyre Lung to global clinical trials,” said Barnaby Balmforth, PhD, Co-Founder and CEO of Biofidelity. “By simplifying genomic profiling, we are making precision medicine more accessible, and this partnership marks a significant step in accelerating trial enrollment and improving patient outcomes.”

Dusty Tenney, CEO of CellCarta, echoed the enthusiasm: “CellCarta is dedicated to advancing precision medicine through specialised laboratory services. Integrating Aspyre Lung into our biomarker testing portfolio strengthens our ability to deliver high-quality, efficient solutions to pharmaceutical and biotech partners.”

This partnership reinforces both companies’ commitment to driving innovation in clinical genomics, ensuring that novel therapies reach patients faster.

More information online